According to our recent payer coverage analysis for hypertension treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for hypertension treatments shows that about 44% of the lives under commercial formularies are unrestricted.
Trends: With a wide variety of generic drugs available, brand name hypertension drugs are rarely prescribed to patients, and costs remain low. Via AIS Health.